Matinas BioPharma rises on tie-up for drug delivery technology
12/01/2023 14:00
** Shares of Matinas BioPharma Holdings Inc MTNB.A rise
3.4% to 55 cents premarket
** Co says it is collaborating with National Resilience Inc
to develop an oral formulation for some drugs using Matinas'
drug delivery platform
** MTNB's lipid nanocrystal (LNC) platform technology is
designed to deliver drugs containing genetic material like mRNA
into target cells
** The collaboration will explore the potential for oral
delivery of genetic material or nucleic acids through LNC -MTNB
** MTNB shares fell 43.4% in the past 12 months
(Reporting by Mariam E Sunny)
((Mariam.ESunny@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing